Stock Analiz

Health Catalyst, Inc. HCAT

Computer Software: Programming Data Processing · IPO 2019 · data as of November 13, 2026

$1.51Market cap $115M
Open the interactive analysis →

Health Catalyst, Inc. (HCAT) is a technology company listed in the US with a market value of about $115M. In the twelve months to September 30, 2026 it had revenue of $272M and net income of -$202M, a net margin of -74.2%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is financial health (4/5); the weakest is shareholder returns (0/5).

Key numbers: a price to free cash flow of 4.5, 5-year revenue growth of 10% a year, a 5-year average ROIC of -17%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 46% below the current price.

About Health Catalyst

Health Catalyst is listed in the US and classified in computer software: programming data processing, IPO year 2019. Revenue went from $73M in 2017 to $311M in 2025, growth of about 19.9% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 29% over three years (dilution for shareholders). It spends 16% of revenue on research and development.

Score: 1.4 / 5

Value1/5
Future growth1/5
Track record1/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • P/FCF below 20
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Positive free cash flow
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF4.5
P/S0.4
P/B0.8
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield22.4%
Shareholder yield4.3%
Intrinsic value vs. price−46%

Growth and quality

Revenue growth (1 yr)1.5%
Revenue growth (5 yrs, per year)10.5%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-46.6%
ROIC (5-yr avg.)-17.2%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 9 years

Fiscal yearTTM202520242023202220212020201920182017
Revenue$272M$311M$307M$296M$276M$242M$189M$155M$113M$73M
Net income-$202M-$178M-$70M-$118M-$137M-$153M-$115M-$60M-$62M-$47M
Free cash flow$26M-$237000$13M-$34M-$37M-$34M-$34M-$34M-$42M-$39M
EPS (diluted)$-2.85$-2.55$-1.15$-2.09$-2.63$-3.23$-2.91$-12.86$-23.76$-12.13
Net margin-74.2%-57.2%-22.7%-39.9%-49.7%-63.3%-60.9%-38.8%-55.1%-64.4%
ROIC—-30.5%-7.2%-16.3%-16.4%-15.6%-16.1%-17.1%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Health Catalyst stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 46% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Health Catalyst pay a dividend?

Not currently.

Is Health Catalyst a good stock to buy?

We do not give buy or sell advice. Health Catalyst scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.